IRVINE, Calif., Aug. 25, 2005 (PRIMEZONE) -- "Investors would be wise to note that some of the greatest innovations come from the ranks of smaller, lesser-followed companies. The absence of multiple layers of bureaucracy often allows the freedom to innovate in ways larger companies may deem too risky or uncertain," said SmallCap Sentinel analyst, D.R. Clark. "While the industry giants tend to focus almost entirely on "home-run" plays that address broad-reaching markets, a fertile field of innovation and opportunity still exists for smaller players."
MIV Therapeutics, Inc. (OTCBB:MIVT), exemplifies this type of small-company innovators having recently received the prestigious Frost & Sullivan 2005 Technology Innovation Award. MIV is a developer of next-generation biocompatible stent coatings and drug delivery technologies for cardiovascular stents and for a broad range of implantable medical devices. The award recognizes the Company's achievements and pioneering work to develop proprietary biocompatible coatings technology to make better, safer vascular stents, medical devices and drug delivery systems.
An informational report "Innovations in Biotechnology" is available free of charge at www.SmallCapSentinel.com
The report addresses issues related to emergent biotechnology potentially affecting companies including Johnson and Johnson (NYSE:JNJ), Pfizer Inc. (NYSE:PFE), and Merck (NYSE:MK).
Interested parties may view additional information about MIVT via this direct link: http://www.trilogy-capital.com/tcp/mivt/factsheet.html
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that will affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid fifteen hundred dollars by MIV Therapeutics Corp. for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.